Ensemble Discovery snares its second big development pact

Ensemble Discovery has hooked another Big Pharma company with the prospects of developing a new class of drugs the developer has dubbed "Ensemblins." Pfizer has inked a deal to collaborate with the Cambridge, MA-based developer using technology that promises to advance popular oral drugs that offer the precise targeting abilities of biologics.

No terms were announced in the pact unveiled this morning, but Ensemble's first deal with Bristol-Myers Squibb back in April provided a $5 million upfront, $7.5 million in research funds and milestones reaching up to $29.5 million.

"This is our second major alliance in less than a year and it attributes a significantly increased value to our platform and its resultant products," says CEO Mike Taylor. "This deal supports Ensemble's position as the leading company exploring new therapeutic opportunities between small molecules and biologics."

And it's a sure bet that Ensemble has more partnership discussions underway. "We have the capability to apply our platform and leverage the progress we've made against a variety of targets and develop programs that would benefit from collaborations at various stages, without being too explicit about partnering strategies," Taylor told FierceBiotech back in the fall of 2008.

- check out Ensemble's release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.